AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company has been added to the Russell 2000® Index, as part of the annual reconstitution of the entire Russell family of indexes that took place on June 25, 2010 following the close of the market. The Russell 2000® Index, a subset of the Russell 3000® Index, measures the performance of the small-cap segment of U.S. equities.
In addition, AVEO was added to the S&P MidCap 400 on June 18, 2010 as part of the quarterly share rebalance of S&P Total Market Index. The S&P MidCap 400 measures the performance of the mid-cap segment of U.S. equities.